A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

BACKGROUND: The immunomodulatory agent pomalidomide in combination with low-dose dexamethasone has demonstrated efficacy and safety for the treatment of relapsed and refractory multiple myeloma (RRMM) in phase 2 and 3 trials. However, these trials enrolled very few Asian patients. METHODS: This phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichinohe, Tatsuo, Kuroda, Yoshiaki, Okamoto, Shinichiro, Matsue, Kosei, Iida, Shinsuke, Sunami, Kazutaka, Komeno, Takuya, Suzuki, Kenshi, Ando, Kiyoshi, Taniwaki, Masafumi, Tobinai, Kensei, Chou, Takaaki, Kaneko, Hitomi, Iwasaki, Hiromi, Uemura, Chie, Tamakoshi, Hiromi, Zaki, Mohamed H., Doerr, Thomas, Hagiwara, Shotaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835896/
https://www.ncbi.nlm.nih.gov/pubmed/27096106
http://dx.doi.org/10.1186/s40164-016-0040-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835896/
https://www.ncbi.nlm.nih.gov/pubmed/27096106
http://dx.doi.org/10.1186/s40164-016-0040-7

Ejemplares similares